Dr. Barlow, M.D., Ph.D., is a renowned expert in neuroscience and neurodegeneration, rare diseases and clinical development of new therapies.
Prior to E-Scape, Dr. Barlow served as CEO of the Parkinson's Institute and Clinical Center, an independent nonprofit organization providing research, clinical trials and patient care for Parkinson's and related disorders.
Before joining the Parkinson's Institute in 2014, Dr. Barlow served as a consultant and advisor to a variety of biotechnology companies addressing neurologic, psychiatric, metabolic and rare genetic diseases. She was acting Chief Medical Officer at Amicus Therapeutics leading the execution, analysis and regulatory interactions that resulted in the approval of the first small-molecule therapy for Fabry disease (migalastat). She also led efforts that resulted in the first proof-of-concept clinical studies in patients for two novel biologic programs for Pompe and Fabry diseases. Previously, Dr. Barlow was a co-founder, Chief Scientific Officer and Chief Medical Officer of BrainCells Inc.
Dr. Barlow received her M.D. from the University of Utah and completed her residency in internal medicine at The New York Hospital, Cornell Medical Center. She went on to earn a Ph.D. in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed specialty training in the endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute. She is an author of approximately 100 peer-reviewed research papers, review articles and book chapters, and is an inventor on numerous patents.